By: Benzinga
UPDATE: Zacks Downgrades Pure Bioscience to Neutral from Outperform on Commercialization Delays
Zacks downgraded Pure Bioscience (NASDAQ: PURE ) from Outperform to Neutral with a $1.75 price target. Zacks said, "[W]e are concerned about the slow sales ramp for the Company s SDC products. Although its lead product PURE Hard Surface is increasingly gaining recognition, sales may take longer time to
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here